ProKidney Corp. Class A Ordinary Shares earnings per share and revenue
On Nov 10, 2025, PROK reported earnings of -0.12 USD per share (EPS) for Q3 25, beating the estimate of -0.13 USD, resulting in a 10.85% surprise. Revenue reached 217.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a +3.70% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 85.00 thousand USD, implying an decrease of -8.33% EPS, and decrease of -60.83% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were ProKidney Corp. Class A Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, ProKidney Corp. Class A Ordinary Shares reported EPS of -$0.12, beating estimates by 10.85%, and revenue of $217.00K, 0% as expectations.
How did the market react to ProKidney Corp. Class A Ordinary Shares's Q3 2025 earnings?
The stock price moved up 3.7%, changed from $2.70 before the earnings release to $2.80 the day after.
When is ProKidney Corp. Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Mar 13, 2026.
What are the forecasts for ProKidney Corp. Class A Ordinary Shares's next earnings report?
Based on 9
analysts, ProKidney Corp. Class A Ordinary Shares is expected to report EPS of -$0.11 and revenue of $85.00K for Q4 2025.